Sotera Health (NASDAQ:SHC) Position Reduced by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Sotera Health (NASDAQ:SHC) by 5.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 261,995 shares of the company’s stock after selling 14,842 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.09% of Sotera Health worth $4,375,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Wedmont Private Capital increased its holdings in shares of Sotera Health by 6.5% in the third quarter. Wedmont Private Capital now owns 10,915 shares of the company’s stock valued at $169,000 after buying an additional 664 shares in the last quarter. First Citizens Bank & Trust Co. grew its position in Sotera Health by 5.0% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 14,287 shares of the company’s stock worth $239,000 after purchasing an additional 677 shares in the last quarter. CWM LLC grew its position in Sotera Health by 86.1% during the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after purchasing an additional 993 shares in the last quarter. GAMMA Investing LLC grew its position in Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares in the last quarter. Finally, TD Asset Management Inc grew its position in Sotera Health by 1.5% during the 2nd quarter. TD Asset Management Inc now owns 123,454 shares of the company’s stock worth $1,465,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Price Performance

Shares of NASDAQ:SHC opened at $13.40 on Friday. The stock has a market capitalization of $3.80 billion, a P/E ratio of 53.04 and a beta of 1.96. The business has a 50-day moving average of $14.71 and a two-hundred day moving average of $14.13. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. During the same period in the prior year, the business earned $0.18 EPS. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities research analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on SHC shares. Citigroup lifted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research report on Thursday, November 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and a consensus target price of $16.08.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.